Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer

Zhao, Liang; Chen, Peiqiong; Fu, Kang; Li, Jinluan; Dai, Yun; Wang, Yuhuan; Zhuang, Yanzhen; Sun, Long; Chen, Haojun; Lin, Qin

doi:10.3389/fonc.2020.551367

Cited by 8 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical findings [42][43][44][45][46] are well documented on the task of measuring PD-L1 related surgical specimens and fine-needle biopsies, yet there is a lack of quantitative research in the field of AI. Our investigation provides deeper insights into optimizing clinical practice of specimen assessment on PD-L1 expression.…”

Section: Discussionmentioning

confidence: 99%

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma

Yan,

Da,

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL) is an aggressive blood cancer known for its rapid progression and high incidence. The growing use of immunohistochemistry (IHC) has significantly contributed to the detailed cell characterization, thereby playing a crucial role in guiding treatment strategies for DLBCL. In this study, we developed an AI-based image analysis approach for assessing PD-L1 expression in DLBCL patients. PD-L1 expression represents as a major biomarker for screening patients who can benefit from targeted immunotherapy interventions. In particular, we performed large-scale cell annotations in IHC slides, encompassing over 5101 tissue regions and 146,439 live cells. Extensive experiments in primary and validation cohorts demonstrated the defined quantitative rule helped overcome the difficulty of identifying specific cell types. In assessing data obtained from fine needle biopsies, experiments revealed that there was a higher level of agreement in the quantitative results between Artificial Intelligence (AI) algorithms and pathologists, as well as among pathologists themselves, in comparison to the data obtained from surgical specimens. We highlight that the AI-enabled analytics enhance the objectivity and interpretability of PD-L1 quantification to improve the targeted immunotherapy development in DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma

Yan,

Da,

et al. 2024

npj Precis. Onc.

View full text Add to dashboard Cite

show abstract

“…One limitation of this study is that PD-L1 staining was conducted on a limited amount of tissue using TMA, which may not adequately reflect tumor heterogeneity. Previous studies investigating the differences in PD-L1 expression between biopsy and surgical tissue in various cancer types have shown a concordance rate of 70% or higher in most cases [ 53 – 56 ]. Additionally, in clinical practice, obtaining small biopsies rather than excising the entire lesion surgically is more common in cases of CUP, suggesting that the results from TMA studies may be more similar to the actual clinical environment.…”

Section: Discussionmentioning

confidence: 99%

Programmed death-ligand 1 expression in carcinoma of unknown primary

Kim,

Koo

2024

BMC Cancer

View full text Add to dashboard Cite

We examined the expression of programmed death-ligand 1 (PD-L1) in carcinoma of unknown primary (CUP) and its potential implications. Tissue microarrays were constructed for 72 CUP cases (histologic subtypes: 22 adenocarcinoma, 15 poorly differentiated carcinoma, 19 squamous cell carcinoma, and 14 undifferentiated carcinoma; clinical subtype: favorable type 17 [23.6%], unfavorable type 55 [76.4%]), with immunohistochemical staining performed for PD-L1 (22C3, SP142, SP263, and 28 − 8), CK7, and CK20 to determine the association between staining results and clinicopathological parameters. In CUP, the PD-L1 positivity rate was 5.6–48.6% (tumor cells [TC] or tumor proportion score [TPS]: 5.6–36.1%, immune cell score [IC]: 8.3–48.6%, combined positive score [CPS]: 16.7%) using different cutoff values for 22C3 (TPS ≥ 1%, CPS ≥ 10), SP142 (TC ≥ 50%, IC ≥ 10%), SP263, and 28 − 8 (TC and IC ≥ 1%). PD-L1 SP142 TC and PD-L1 SP263 IC showed the lowest (5.6%) and highest (48.6%) positivity rates, respectively. The PD-L1 positivity rate did not significantly differ based on the histologic subtype, clinical subtype, or CK7/CK20 across clones. Considering TC κ ≥ 1%, TC κ ≥ 50%, IC κ ≥ 1%, and IC κ ≥ 10%, the PD-L1 positivity rate was TC = 4.2–36.1% and IC = 9.7–48.6%; the overall agreement between antibodies ranged from 69.4 to 93.1%, showing fair or better agreement (κ ≥ 0.21). In CUP, PD-L1 positivity varied depending on antibodies and scoring systems, with no difference observed according to histologic or clinical subtypes.

show abstract

“…Various trials comparing PD-L1 expression in biopsy and matched surgical specimens revealed controversial results [9][10][11][12][13]. Some authors described a poor correlation of PD-L1 expression on tumour cells between biopsy and corresponding surgical specimens [8; 9], whereas other studies found a good concordance of PD-L1 testing between biopsy samples and matches resected specimens [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Correlation of PD-L1 Expression on Tumour Cells Between Diagnostic Biopsies and Surgical Specimens of Lung Cancer in Real Life With Respect to Biopsy Techniques and Neoadjuvant Treatment

Gompelmann

Sinn

Brugger

et al. 2022

Preprint

View full text Add to dashboard Cite

Purposes: Programmed death-ligand 1 (PD-L1) testing is performed mainly on biopsy specimens in patients with advanced lung cancer. It is questionable whether the small amount of tissue analysed in biopsies may represent the true PD-L1 expression of a tumour.Methods: In this retrospective study, PD-L1 expression on tumour cells derived from bronchoscopy brush cytology, endobronchial-ultrasound guided transbronchial needle aspiration (EBUS-TBNA), endobronchial biopsy, transbronchial biopsy (TBB) and computed tomography (CT)-guided transthoracic biopsy was compared to the PD-L1 expression of the corresponding surgical resection in lung cancer patients with regard to neoadjuvant treatment in-between.Results: A quantitative comparison between the diagnostic biopsy of the primary tumour with corresponding resected surgical specimens in a total of 113 lung cancer patients (60% male, mean age 65 ± 9 years) revealed a statistically significant correlation of PD-L1 expression on tumour cells (r=0.58, p<0.001), for patients without neoadjuvant treatment in-between and for patients who underwent neoadjuvant treatment (both p<0.001). Using a cut-off value of ≥50% PD-L1 TPS for comparing the biopsy samples and resected specimens, the concordance rate was 78% with a Cohen´s Kappa of 0.45.Conclusion: A statistically significant concordance for PD-L1 expression on tumour cells between biopsies from primary lung tumour and resected specimen was found, but of uncertain clinical accuracy. The use of a cut-off value of ≥50% PD-L1 TPS resulted only in a moderate agreement. Therefore, the interpretation of the PD-L1 determined form biopsy specimens status should only be considered with caution for treatment decisions.

show abstract

Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer

Cited by 8 publications

References 43 publications

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma

Programmed death-ligand 1 expression in carcinoma of unknown primary

Correlation of PD-L1 Expression on Tumour Cells Between Diagnostic Biopsies and Surgical Specimens of Lung Cancer in Real Life With Respect to Biopsy Techniques and Neoadjuvant Treatment

Contact Info

Product

Resources

About